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Human herpesvirus 6 (HHV-6) can activate the human immunodeficiency virus (HIV) promoter and
accelerate cytopathic effects in HIV-infected human T cells. This study examines the regions of the HIV
promoter required for HHV-6 transactivation in a heterogeneous population of primary human T Iymphocytes
with or without antigenic stimulation. Two different strains of HHV-6, GS and Z29, transactivated the HIV
promoter. The GS strain transactivated the promoter in both stimulated and resting T cells, while the Z29
strain increased HIV promoter activity only in stimulated T cells. Three DNA clones containing HHV-6(GS)
genomic fragments transactivated the HIV promoter in cotransfected T cells. A 21.4-kb DNA clone, pZVB70,
showed the highest transactivating ability, while two other DNA fragments, pZVB10 (6.2 kb) and pZVH14 (8.7
kb), showed lower activity. One of these clones, pZVH14, activated the HIV promoter construct containing a
mutation in the NFKB site. However, this mutated NFKB promoter was not transactivated during HHV-6(GS)
infection or after cotransfection with pZVB70 or pZVB10. These data indicate that the NFcB sites of the HIV
promoter are essential for its transactivation during HHV-6(GS) infection. By increasing HIV promoter
activity in primary T lymphocytes, HHV-6 may consequently increase HIV replication, leading to an increase
in the cytopathic effect on coinfected human T cells.
Human CD4+ T lymphocytes are the primary target of the
human immunodeficiency virus (HIV) (4, 20, 31). Infection
with HIV results in the eventual development of AIDS (9,
10, 23). HIV replication can be shown in only a small
percentage of T cells in vivo and seems to persist for long
periods of time in a latent phase (2). Because the virus exists
in a latent phase, infected individuals may not develop
clinical manifestations ofAIDS for years after the initial HIV
infection (2, 15). The latent HIV virus can be reactivated by
various agents such as antigen, mitogen, or cytokine stimu-
lation (7, 21). A wide range of antigenic stimulation and viral
infections have been demonstrated to activate the HIV
promoter in various cell lines (13, 22, 40). However, it is not
clear to what extent these events occur in vivo, and the
mechanisms involved are not yet completely understood.
A new lymphotropic herpesvirus, human herpesvirus 6
(HHV-6), has recently been isolated from peripheral blood
lymphocytes of patients with AIDS (35, 39), from patients
with lymphoproliferative disorders (35), and from infants
with exanthem subitum (34, 38). Immunological and molec-
ular analyses have demonstrated that the new herpesvirus is
distinct from other human herpesviruses (17, 18, 25). HHV-6
productively infects CD4+ human T cells; however, the
HHV-6 strains show variations in their ability to infect
various T cells and T-cell lines (41). They also differ in
antigenic properties (41) and exhibit DNA restriction site
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heterogeneity (5). The prototype strain, HHV-6(GS), in-
fected a number of T-cell lines as well as human B lympho-
cytes, glioblastoma cells, and megakaryocytic cells (26). In
contrast, HHV-6(Z29), isolated from a Zairian AIDS patient,
infected phytohemagglutinin-stimulated lymphocytes from
cord blood or from adult peripheral blood but failed to
replicate in unstimulated lymphocytes and certain T-cell
lines (5). Recently, we have grown HHV-6(Z29) in the
Molt-3 T-cell line, in which HHV-6(GS) failed to replicate.
HHV-6 infects many of the same target cells as HIV (26),
and in vitro, HHV-6(GS) can also productively coinfect
HIV-infected CD4+ T cells (6, 24, 26). One study showed
that this leads to accelerated cytopathic effects in compari-
son with HIV or HHV-6 infection alone (26). In addition, our
previous studies have demonstrated that the HIV long
terminal repeat (LTR) is activated in HHV-6-infected T-ceil
lines (14). Activation of the HIV LTR leads to increased
HIV gene expression, which ultimately leads to a higher
level of virus replication. These observations suggest that
HHV-6 can act as a cofactor in the development and
possibly in the progression of AIDS.
To study the activation of HIV by HHV-6 under more
physiologic conditions, we have assessed whether or not
HHV-6 infection of primary human T lymphocytes can
activate the HIV promoter. Furthermore, the effects of
specific antigenic stimulation in combination with infection
by two strains of HHV-6 were examined. Results of the
study indicate that HHV-6 strains GS and Z29 can activate
the HIV promoter in primary human T lymphocytes and
differed in their dependency on antigenic stimulation for
transactivation. Transactivation by HHV-6(GS) involves the
NFKB region of the HIV LTR. We have also identified three
2895
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different cloned HHV-6(GS) DNA fragments that transacti-
vate the HIV promoter after cotransfection into human T
cells.
MATERIALS AND METHODS
DNA and plasmids. The HIV chloramphenical acetyltrans-
ferase (CAT) plasmid has been described in detail previously
(19). Briefly, the construct contains both the 3' untranslated
region and the repeat sequences of the HIV LTR aligned
with the CAT gene. The -147 CAT plasmid was constructed
by deleting a fragment of the HIV LTR at the AvaI site as
described elsewhere (13). The -57 CAT plasmid was kindly
provided by Joseph Sodroski (Harvard Medical School,
Boston, Mass.) (33). The HIV LTR plasmid containing the
mutated NFKB site was kindly provided by Gary Nabel (27).
BamHI plasmid libraries of the HHV-6 genome were gener-
ated as described previously (17).
HHV-6 viral strains and preparation. The human T-cell
lines HSB-2 (ATCC CCL120.1 CCRF-HSB-2) and Molt-3
(ATCC CRL 1552) were grown in RPMI 1640 medium
supplemented with fetal bovine serum and antibiotics. Two
strains of HHV-6 were used in this study. HHV-6(GS) was a
gift from R. C. Gallo, National Cancer Institute, Bethesda,
Md.; HHV-6(Z29) was a gift from P. Pellet, Centers for
Disease Control, Atlanta, Ga. HHV-6(GS) was grown in
HSB-2 cells, and HHV-6(Z29) was grown in Molt-3 cells.
Infected cells were collected 6 to 8 days postinfection when
more than 80% of the cells were positive for viral antigens in
an indirect immunofluorescence assay (IFA) by using
HHV-6 specific monoclonal antibodies (3). These infected
cells were frozen and thawed twice, and the 50% tissue
culture infectivity dose was determined by procedures de-
scribed previously (3, 41) on HSB-2 cells for HHV-6(GS)
and Molt-3 cells for HHV-6(Z29).
Human T lymphocytes. Fresh mononuclear cells were
isolated from the peripheral blood of purified protein deriv-
ative (PPD)-immune, normal human donors by using Hy-
paque-Ficoll (13). These cells (105 per well) were then
stimulated for 6 days with tuberculin PPD (5 RI/ml) in 96-well
round-bottom plates. Lymphoblasts were separated from
small mononuclear cells and dead cells by using a 35 to 45%
Percoll step gradient. The cells collected at the interface
between 35 and 45% were judged to be >98% lymphoblasts
by microscopic examination. By immunofluorescence, 85 to
89% of the cells were judged to be CD3 + (Ortho T3
antibody). These cells are referred to in this report as T-cell
lymphoblasts and were used for transfections.
Transfection and infection of T cells. The T-cell lympho-
blasts were transfected by a DEAE-dextran method (1).
Briefly, 1 p.g of the appropriate DNA in the presence of 700
,ug of DEAE-dextran per ml was added to T-cell lympho-
blasts or the T-cell line HSB-2 for 3 h at 37°C. The cells were
then treated with dimethyl sulfoxide (10%) for exactly 1 min.
After washing, the cells were placed in fresh RPMI 1640
medium containing 10% human serum. A portion of the
transfected T cells was then infected with HHV-6(GS) or
HHV-6(Z29) at a multiplicity of infection of 0.01 by incubat-
ing the T-cell pellet for 1 h at 37°C with cell lysates of
HHV-6(GS) or HHV-6(Z29). In certain experiments, HHV-
6(GS) DNA clones were cotransfected with the HIV pro-
moter constructs into primary T lymphoblasts or the T-cell
line HSB-2. The transfected and/or infected T cells (2 x 104
per well) were then added to either irradiated, adherent,
autologous mononuclear cells (105 per well) alone or cells
that had been incubated overnight with tuberculin PPD (5
[lI/ml) in 96-well flat-bottom plates as described earlier (13).
These cell populations are referred to as resting transfected
T cells or stimulated transfected T cells, respectively. Five
days later, the transfected T cells were collected, washed
twice with phosphate-buffered saline, counted, and used in
CAT assays. Since a background level of CAT activity is
observed in fresh T-cell blasts as a result of antigenic
stimulation, cells were collected 5 days after transfection in
order to lower this background level of CAT activity.
CAT assays. Transfected T cells, collected after 5 days,
were resuspended in 100,ul of sonication buffer (0.25 M Tris
HCl, pH 7.4). The cell number was adjusted to 2 x 106/100
,li so that the same number of cells was used in each CAT
assay. Cellular extracts were prepared by a single freeze
(-70°C)-thaw (37°C) cycle and 1 min of sonication, followed
by centrifugation to remove cell debris. CAT assays using
[14C]chloramphenicol and thin-layer chromatography have
been described in detail previously (12). CAT assays using
[3H]acetyl coenzyme A ([3H]acetyl-CoA) have been de-
scribed by Neuman et al. (30). Briefly, 50 ,ul of the cell
lysates, [3H]acetyl-CoA, and chloramphenicol was mixed in
100 mM Tris HCl, pH 8.0. An organic scintillation cocktail
(Econofluor; Hewlett-Packard) was layered over this mix-
ture, and the samples were incubated at 37°C. The samples
were counted in a beta scintillation counter at hourly inter-
vals after initiation of the assay. Units of CAT activity in
each cell lysate were calculated according to a standard
curve established with a CAT sample (Pharmacia) of known
enzymatic activity.
RESULTS
HHV-6(GS) transactivates the HIV LTR promoter in pri-
mary human T lymphoblasts. The primary T lymphoblasts
used in this study have been described previously (13) and
consist of approximately 85% CD3+, 59% CD4+, and 32%
CD8+ cells. These lymphoblasts were transfected with the
HIV CAT construct, containing the HIV promoter, by using
DEAE-dextran. After transfection, a portion of the T cells
was infected with HHV-6(GS). Five days after infection with
HHV-6(GS), 30 to 40% of the cells reacted with HHV-6-
specific monoclonal antibodies (3) by IFA. This result indi-
cated that the transfected cells were productively infected by
HHV-6(GS). None of the uninfected lymphocytes reacted
with HHV-6-specific monoclonal antibodies, indicating the
absence of endogenous HHV-6 virus. After 5 days in cul-
ture, lysates were prepared from the transfected cells and
CAT activity was measured (Fig. 1). Lysates from trans-
fected T cells without antigen (PPD) stimulation and without
HHV-6 infection converted 9% of the chloramphenicol sub-
strate to its acetylated forms, as shown by thin-layer chro-
matography (Fig. 1A). This lysate contained a total of 0.12 U
of CAT activity (Fig. 1B and Table 1). Transfected T-cell
blasts activated with antigen showed higher CAT activity
than did unstimulated T cells. Lysates from these cells
converted 79% of the chloramphenicol to its acetylated
forms and contained a total of 0.46 U of CAT activity (Fig.
1C). This represents a fourfold increase in CAT activity after
antigenic stimulation (Table 1). These experiments confirm
our previous studies, which showed that antigen activation
of primary T cells can activate the HIV promoter (13).
Infection of these transfected T cells with HHV-6(GS)
resulted in transactivation of the HIV promoter in both
resting and stimulated T cells (Fig. 1A and C). When lysates
from unstimulated, GS-infected T-cell lymphoblasts were
tested for CAT activity, there was a conversion of75% of the
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FIG. 1. CAT enzymatic activity from primary T-cell lysates. (A) Thin-layer chromatography of ['4C]chloramphenicol reacted with cell
lysates from stimulated T cells (PPD+) and resting T cells (PPD-) either infected with HHV-6 (+) or uninfected (-). (B) Standard curve of
CAT enzymatic activity obtained by using a rapid method that utilizes [3H]acetyl-CoA. This standard curve is used to calculate the amount
of CAT activity in cell lysates. As little as 0.01 U of enzymatic activity can be detected per lysate. (C) CAT activity measured in T-cell lysates
by the rapid method.
substrate, corresponding to 0.64 U of CAT activity, while
lysates from activated, infected T cells showed a 99%
conversion of the substrate and 2.61 U of CAT activity (Fig.
1A and Table 1). These values represent 5- and 22-fold
increases in CAT activity without and with antigenic stimu-
lation, respectively. Since CAT assays with [3H]acetyl-CoA
TABLE 1. Evidence that the enhancer region of the HIV LTR is
required for HHV-6(GS) transactivationa
CAT activity (total U in cell lysate)
Promoter T-cell Uninfected cells HHV-6-infected cellsdonorb
_ + -+
HIV CAT 1 0.12 0.45 (4)c 0.78 (7) 3.04 (25)
2 0.12 0.45 (4) 0.64 (5) 2.61 (22)
-147 CAT 1 0.24 1.11 (5) 2.97 (12) 3.84 (16)
2 0.19 1.08 (6) 2.08 (11) 3.24 (17)
3 0.16 0.31 (2) 1.49 (9) 2.32 (15)
-57 CAT 1 <0.01 <0.01 0.05 0.05
2 <0.01 <0.01 0.03 0.04
Mutant NFKB- 2 <0.01 <0.01 <0.01 <0.01
CAT
3 <0.01 <0.01 <0.01 <0.01
aVarious promoters were transfected into primary T cells by using DEAE-
dextran. The transfected cells were either cultured directly with autologous,
irradiated mononuclear cells or infected with HHV-6(GS) and then added to
feeder cells. Antigen was then added to appropriate cultures. Cells were
incubated for 5 days, collected, and lysed, and CAT activity was measured.
Transfected cells were infected with HHV-6(GS) at multiplicity of infection of
0.01. Some cell cultures were given the antigen PPD (+), while others were
given medium (-).
b Cells from at least two different donors were transfected with each
promoter. Cells from each donor were transfected twice.
c Values in parentheses represent the increase in CAT activity based on the
enzymatic activity found in noninfected, resting T cells.
are more quantitative and convenient (30), subsequent cell
lysates were all measured by this rapid method.
These data show that infection of primary T lymphoblasts
with HHV-6(GS) activates the HIV promoter in both resting
and stimulated primary T cells. Although the activation in
resting cells is not as pronounced (5- to 7-fold) as in
antigen-activated T cells (22- to 25-fold), the data clearly
demonstrate that HHV-6(GS) can infect unstimulated pri-
mary T cells and will activate the HIV promoter, which
otherwise remains quiescent. Although activation of resting,
primary T cells by HHV-6 may have also contributed to the
low level of transactivation of the HIV promoter, this alone
cannot account for all of the transactivation activity ob-
served.
Transactivation of the HIV promoter in antigen-activated
primary human T lymphocytes by HHV-6(Z29). Soon after
the GS strain of HHV-6 was identified, a new variant strain
of HHV-6 was identified which was designated HHV-6(Z29)
(5). HHV-6(Z29) is related to the GS strain both antigenically
and genetically (17, 25, 41). Both strains infect human T
lymphocytes but seem to have a preference for distinct
subsets. These subsets are still not clearly defined. The Z29
strain can effectively infect the Molt-3 T-cell line but not
HSB-2, while the GS strain infects HSB-2 but not Molt-3.
Both HHV-6 strains can infect primary human phtyohemag-
glutinin-stimulated blasts, but HHV-6(Z29) failed to repli-
cate in unstimulated peripheral blood lymphocytes (41). In
this study, primary T lymphoblasts specific for the antigen
tuberculin PPD were transfected with the HIV CAT con-
struct and then infected with HHV-6(Z29). After 6 days, the
cells were collected and tested for infection with HHV-
6(Z29) by IFA using cross-reactive HHV-6(GS) monoclonal
antibodies (41). T lymphocytes stimulated with PPD during
the HHV-6(Z29) infection had enlarged cells and were pos-
A
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FIG. 2. Total CAT activity from resting (-) and stimulated (+) T
cells either infected with HHV-6(Z29) (+) or left uninfected (-).
Shown are representative results from two different donors; the
values in parentheses show the increase in total CAT activity
compared with the activity of unstimulated T lymphoblasts. The
total units ofCAT activity in unstimulated T cells are 0.09 for donor
2 and 0.011 for donor 4.
itive for viral antigens. However, T cells infected with
HHV-6(Z29) in the absence of antigen stimulation showed
no viral antigen-positive cells.
After 6 days of culture, transfected T lymphocytes were
collected, washed, and lysed, and the CAT activity was
measured from the cell lysates. The results showed that the
HIV CAT promoter was activated only in HHV-6(Z29)-
infected human T lymphocytes that had been stimulated with
antigen. This was explained by the finding that productive
infections of T lymphocytes with HHV-6(Z29), as deter-
mined by IFA with HHV-6-specific antibodies, occurred
only in cells stimulated by antigen. Unstimulated cells did
not support viral infection, nor did they demonstrate HIV
CAT promoter activation (0.09 U ofCAT activity in donor 2;
0.011 U of CAT activity in donor 4). As noted above, in
primary T cells not infected with HHV-6(Z29), the HIV
promoter was activated by antigenic stimulation (19-fold in
donor 2, with 1.75 U of CAT activity; 140-fold in donor 4,
with 1.54 U of CAT activity) (Fig. 2). When the transfected
T cells were infected with HHV-6(Z29) in the absence of
antigen, no increase in CAT activity was observed (0.97-fold
in donor 2, with 0.087 U of CAT activity; 0.7-fold in donor 4,
with 0.008 U of CAT activity). However, when the trans-
fected T cells were infected with HHV-6(Z29) and activated
with PPD, a 46- to 404-fold increase in total CAT activity and
IlWo(ctU4i%; iUCAG
/ I
-642
FIG. 3. Schematic diagram of the HIV promoters used in this
study. -57 CAT contained only one Spl site and the TATA box as
well as the tat target sequences. The -147 CAT plasmid contained
the NFKB site, all of the Spl sites, the TATA box, and the tat target
region but had lost the negative regulatory region (NEG reg). The
mutant NFKB promoter had all regulatory regions intact but had two
regions within the NFKB site changed from GGG to TCT. The intact
HIV CAT promoter had no sequence changed or deleted.
3-fold increase in activity over antigenic stimulation alone
were noted (4.18 U of total CAT activity in donor 2; 4.44 U
of total CAT activity in donor 4). These data indicate that
HHV-6(Z29) transactivated the HIV LTR in antigen-stimu-
lated, primary, human T lymphocytes and that transactiva-
tion by HHV-6(Z29) requires productive infection ofprimary
T lymphocytes.
Transactivation of the HIV promoter in human T lympho-
cytes by HHV-6(GS) depends on the presence of a functional
NFKB enhancer site. Earlier studies on the activation of the
HIV promoter in primary human T lymphocytes showed that
activation of the HIV promoter was influenced by the NFKB
enhancer region as well as an upstream region that exerts
negative regulation (13). Several different constructs of the
HIV promoter, described in Fig. 3, were transfected into
PPD-specific human T lymphoblasts. The HIV promoter
designated -57 CAT contains one of the Spl sites as well as
the TATA site. This promoter has been shown to be active in
other cell types (COS-7; data not shown), but little or no
promoter activity has ever been observed in primary T
lymphocytes (13) (Table 1). The promoter designated -147
CAT retained the NFKB binding region as well as the three
Spl sites and the TATA box (Fig. 3). This promoter does not
have the negative regulatory region, and therefore the CAT
activity expressed after transfection into primary T lympho-
blasts is somewhat higher than with the intact promoter
(Table 1). T lymphoblasts transfected with -147 CAT and
then infected with HHV-6(GS) consistently showed evi-
dence of transactivation (9- to 17-fold increase in CAT
activity). This finding indicates that the negative regulatory
region is not primarily involved in the increased promoter
activity due to HHV-6(GS) infection. These results also
show that the DNA sequences responsible for HHV-6(GS)
transactivation must be within the -147 to -57 region. To
further locate the specific promoter region responsible for
HHV-6 transactivation, the HIV LTR plasmid containing a
mutated NFKB CAT promoter was transfected into primary
T lymphocytes. This promoter contained two sequences
DONOR 2A
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1 3.0-
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TABLE 2. Evidence that HHV-6(GS) DNA plasmids can
transactivate the HIV promoter'
CAT activity (total U in cell lysate)
HIV-CAT HIV-CAT + HHV-6(GS) plasmid
T-cell stimulatAntigenic Antigenic stimulationT-el stimulation Plasmid
donor
_ + -+
2 0.04 1.8 (45)b pZVB70 4.05 (101) 10.84 (271)
3 0.12 0.26 (2) 4.54 (38) 10.88 (91)
3 0.15 1.95 (13) 3.85 (26) 11.55 (77)
2 0.1 1.24 (12) pZVH14 1.77 (18) 2.58 (26)
3 0.24 1.95 (8) 2.37 (10) 3.14 (13)
3 0.19 1.46 (8) 1.77 (9) 2.87 (15)
1 0.02 1.35 (68) pZVB10 0.26 (13) 1.68 (84)
4 0.01 1.54 (154) 0.35 (35) 1.83 (183)
1 0.02 1.7 (85) pZVB9 0.02 1.12 (56)
3 0.24 1.95 (8) 0.17 1.51 (6)
3 0.38 1.91 (5) pZVB15 0.07 2.79 (7)
4 0.01 1.54 (154) 0.05 (5) 1.87 (187)
2 0.1 1.24 (12) pZVB43 0.17 (2) 1.37 (14)
3 0.15 1.95 (13) 0.14 (1) 1.63 (11)
3 0.19 1.46 (8) 0.18 (1) 1.69 (9)
a Plasmids containing HHV-6(GS) DNA were cotransfected with HIV CAT
into primary T cells. CAT activity was measured after 5 days from cell lysate.
Antigen activation of transfected cells was as described for Table 1.
b See Table 1, footnote c.
within the NFKB sites that had been changed from GGG to
CTC (Fig. 3), changes that in the NFKB site eliminate the
activation of the HIV promoter by the NFKB protein (27).
This mutation in the NFKB sites abolished the HIV promoter
activity induced in primary T lymphoblasts both by antigen
and by HHV-6(GS) infection. Although no CAT activity
could be detected in the lysates from these cells, IFA
indicated that the population of T cells transfected with the
mutant NFKB promoter and infected with HHV-6(GS) con-
tained enlarged cells highly positive for HHV-6(GS) proteins
(data not shown). This result showed that the transfected T
cells were productively infected with HHV-6(GS) and sug-
gests that HHV-6(GS) requires the NFKB region for trans-
activation of the HIV promoter.
At least three different DNA segments cloned from the
HHV-6(GS) genome can transactivate the HIV promoter when
cotransfected into primary T lymphocytes. The HHV-6(GS)
genome was digested with the restriction enzyme BamHI or
HindlIl, and the resulting fragments were ligated into the
Bluescript vector (17). Six different HHV-6(GS) DNA frag-
ments representing about 40% of the total viral genome and
varying in length from 3.3 to 21.4 kb (17) were used in these
studies. Each HHV-6(GS) fragment was cotransfected with
HIV CAT into the primary T-cell populations, and CAT
activity was measured in cell lysates 5 days later. The largest
fragment, pZVB70 (21.4 kb), showed a dramatic transacti-
vating effect on the HIV promoter (Table 2). In the absence
of antigen, this fragment increased HIV promoter activity 26
to 101 times over the activity expressed in unstimulated T
cells. When the cells were stimulated with antigen, there was
a 77- to 271-fold increase in total CAT activity, which was 6-
to 42-fold over the antigenic stimulation alone. It was the
major DNA fragment from HHV-6(GS) that showed this
level of activity, and as such it was designated a high
transactivator of the HIV promoter.
Two other HHV-6(GS) fragments, designated pZVH14
and pZVB10, marginally transactivated the HIV promoter
A
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FIG. 4. Total CAT activity from transfected HSB-2 cells. (A)
HSB-2 cells were transfected with HIV CAT only (-) and then
infected with HHV-6(GS). Cells were also cotransfected with HIV
CAT and various HHV-6 cloned DNA fragments: pZVB70 (B70),
pZVH14 (H14), pZVB10 (B10), and pZVB43 (B43). (B) HSB-2 cells
were also transfected with mutant NFKB CAT plasmid. Some of the
cells were infected with HHV-6(GS), while others were left unin-
fected (-). A portion of the cells were cotransfected with various
HHV-6 DNA clones as described above.
(Table 2) when expressed in the absence of antigen stimula-
tion. The DNA clone pZVH14 contained a 8.7-kb fragment
from HHV-6(GS), while clone pZVB10 contained a 6.2-kb
fragment. Since these HHV-6(GS) DNA clones showed only
low-level activation of HIV CAT in the absence of antigen
and promoter activity in antigen-stimulated cells increased
only slightly, we have designated these clones low transac-
tivators. The highest transactivation was observed when
cotransfected T lymphocytes were stimulated with antigen,
suggesting an additive effect of antigenic stimulation and the
HHV-6(GS) gene product(s) on HIV promoter activity.
Table 2 also shows data for three fragments cloned from
HHV-6(GS) that failed to transactivate the HIV promoter.
These DNA clones were designated pZVB9 (11.8-kb frag-
ment), pZVB43 (8.3-kb fragment), and pZVB15 (3.3-kb
fragment). From these results, it can be concluded that
HHV-6 contains at least three different gene segments that
can transactivate the HIV promoter.
To confirm the data observed in primary T lymphocytes,
these fragments were also cotransfected with HIV CAT into
the human T-cell line HSB-2 (Fig. 4A). As previously
demonstrated (14), infection of the transfected HSB-2 cells
with HHV-6(GS) resulted in an increase in CAT activity
(threefold), indicating that the HIV promoter was also trans-
activated in a T-cell line. Cotransfection of HHV-6(GS)
DNA clone pZVB70 and HIV CAT resulted in a dramatic
increase in CAT activity (58-fold; Fig. 4A). Plasmid pZVB70
transactivated HIV CAT to a much greater extent than did
HHV-6(GS). It was also observed that plasmid pZVH14,
when cotransfected with HIV CAT into the HSB-2 T-cell
line, activated promoter activity to a higher level than did
HHV-6(GS). The CAT activity in these samples increased
30-fold over the activity of HSB-2 cells transfected with HIV
CAT alone. This finding suggests that during HHV-6(GS)
infection, the gene products from these DNA segments are
under some type of regulation that is lost when the genes are
cloned into plasmids. Cotransfection of HSB-2 cells with
two other HHV-6 fragments, pZVB10 and pZVB43, did not
show any transactivation of HIV CAT. These data confirm
our observation in primary T lymphocytes, that the gene
segments contained in plasmids pZVB70 and pZVH14 trans-
activated the HIV promoter; however, unlike the situation
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TABLE 3. Transactivation of the mutant NFKB promoter with
HHV-6(GS) DNA clonesa
CAT activity (total U)
Mutant NFKB Mutant NFKB + HHV-6(GS) plasmid
T-cell Antigen stimulation Antigenic stimulation
donor Plasmid
3 <0.01 <0.01 pZVH14 0.07 (7)b 0.07 (7)
2 <0.01 <0.01 0.04 (4) 0.06 (6)
2 <0.01 <0.01 pZVB70 <0.01 <0.01
3 <0.01 <0.01 <0.01 <0.01
2 <0.01 <0.01 pZVB10 <0.01 <0.01
4 <0.01 <0.01 <0.01 <0.01
a HHV-6(GS) DNA clones were cotransfected with the mutant NFKB
promoter (see Fig. 3) into primary T cells. Cells were incubated for 5 days as
described for Table 1. Total CAT activity was measured in cell lysates.
bSee Table 1, footnote c.
for primary T cells, pZVB10 failed to activate the HIV
promoter in HSB-2 cells.
To determine whether mutations in the NFKB site of the
HIV promoter affected the transactivation by cloned HHV-
6(GS) DNA fragments, the three transactivating fragments
were cotransfected into primary T cells with the promoter
containing the NFKB mutation. The resulting promoter
activities are shown in Table 3. Mutation in the NFKB site
completely abolished the ability of the pZVB70 and pZVB10
clones to transactivate. However, with the pZVH14 clone, a
slight but consistent transactivation was observed (four- to
sevenfold) that was less than the transactivation seen with
the intact HIV promoter. The transactivation of the mutated
NFKB promoter by pZVH14 was not dependent on antigenic
stimulation of the T cells, since it was not enhanced by the
presence of antigen. Similar results were observed when
these cloned DNA fragments were cotransfected with the
mutated NFKB promoter into HSB-2 cells (Fig. 4B). The two
DNA clones, pZVB70 and pZVB10, failed to transactivate
the mutated NFKB promoter, but pZVH14 showed slight
transactivation (8- to 10-fold). This finding confirmed the
results in primary T lymphocytes. Together, these data
suggest that the transactivating gene(s) included within the
pZVH14 clone may not totally depend on an intact NFKB
site but may also use other target DNA region(s) in the
promoter.
DISCUSSION
Our studies demonstrate that two strains of HHV-6, GS
and Z29, can infect and activate the HIV promoter in
primary, human T lymphocytes. However, these two strains
of HHV-6 showed distinct differences in ability to transac-
tivate the HIV promoter, related to the ability of the two
strains to productively infect resting T lymphocytes. HHV-
6(GS) infected both stimulated and unstimulated human T
cells, while HHV-6(Z29) infected only stimulated T cells.
This observation confirms the results of Wyatt et al. (41),
who showed that HHV-6(Z29) failed to replicate in nonacti-
vated peripheral blood lymphocytes. HHV-6(Z29) was un-
able to infect resting T cells, and no transactivation of the
HIV promoter was observed. However, HHV-6(GS) trans-
activated the HIV promoter even in resting T cells. These
data suggest that active replication of HHV-6(Z29) and
subsequent production of its gene products are required for
transactivation of the HIV promoter. It is also possible that
HHV-6(Z29) requires essential cellular elements that are
provided by antigenic stimulation of T cells for its replica-
tion, and thus the activation of the HIV promoter by Z29
may require cellular cooperation. Ensoli et al. (8) have
previously shown that HHV-6(GS) infection of HIV-infected
T cells increases the steady-state level of HIV mRNA that
parallels CAT enzymatic activity. It is quite possible that
similar mechanisms are responsible for the increase in CAT
enzymatic activity observed here. Studies are currently
under way to examine the mechanism of action by the cloned
gene fragments.
Certain difficulties are inherent in these types of experi-
ments. We have observed differences in HIV promoter
activation between different donors and even from the same
donor when cells were donated at different times (6 months
later). Without HHV-6 infection or antigenic stimulation, the
background CAT activity ranged between 0.01 and 0.38 total
U of enzyme activity. Because the increase in promoter
activity is based on the background activity between donors
or experiments, this parameter cannot be used to compare
promoter activity but must be used to measure transactiva-
tion within a single experiment. This was not expected, since
these experiments require many steps of long incubation
periods. Because of the large number of peripheral blood
mononuclear cells needed for each experiment (>100 x 106),
donors were only bled every 6 weeks. However, each
transfection was done at least twice on two different healthy
adult human donors. Therefore, when transactivation was
observed consistently in all experiments, we concluded that
there was activation of the HIV promoter in these situations.
A number of experiments were performed to identify the
region of the HIV promoter required for transactivation by
HHV-6(GS). In earlier studies, several deletions or muta-
tions in the HIV promoter were used to determine which
promoter regions were essential for control of the promoter
activity during primary in vitro T-cell stimulation (13). These
altered promoters were also used in this study, and the
results showed that the NFKB region was essential for
transactivation during HHV-6(GS) infection. Thus, an HIV
promoter containing mutated sequences within the NFKB
region was no longer activated by HHV-6(GS) infection. It is
not known whether HHV-6(GS) directly activates the NFKB
cellular protein or, alternatively, a HHV-6(GS) gene prod-
uct(s) binds directly to the NFKB region. However, these
results to indicate that this particular promoter region seems
to be essential for HHV-6(GS) transactivation during an
active infection. Similar results were observed when the
human T-cell line HSB-2 was transfected with the mutated
NFKB promoter and then infected with HHV-6(GS). HHV-
6(GS) is not unique in using the NFKB site, since it has been
noted that other herpesviruses, such as herpes simplex virus
type 1, cytomegalovirus, and Epstein-Barr virus, also act on
the NFKB region of the HIV promoter (22).
The genome of HHV-6(GS) has been estimated to be
about 170 kb in length (17, 18), which should code for more
than 70 proteins. A number of DNA cloned fragments from
the GS genome were examined in this study to determine
whether they code for products that transactivate the HIV
promoter. Several HHV-6(GS) DNA clones, comprising
about 40% of the viral genome, were individually cotrans-
fected with HIV CAT into primary human T lymphocytes.
Three different non-cross-hybridizing DNA clones transac-
tivated the HIV promoter, and at present it is not known
whether other HHV-6 DNA fragments are also able to
transactivate the HIV promoter. The DNA clone showing
the highest level of transactivation (pZVB70) contained 21.4
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kb of HHV-6(GS) DNA. It is possible that more than one
gene product expressed from this plasmid is responsible for
the high level of transactivating ability of this plasmid. Since
these fragments were not inserted into a eukaryotic expres-
sion vector, their expression requires endogenous promoter
activity. It can thus be inferred from these data that at least
some of the HHV-6 promoters must be active in both
stimulated and unstimulated primary T cells. Two other
plasmids containing HHV-6(GS) fragments also transacti-
vated the HIV promoter in primary T cells. These plasmids
were pZVH14, which contained an 8.7-kb viral fragment,
and pZVB10, which contained a 6.2-kb fragment. To deter-
mine the nature of the open reading frames present in these
fragments, the DNA was sequenced (data not shown). From
this information, several genes have been identified and are
currently been subcloned and tested for transactivating
ability on the HIV promoter in human T cells.
Although the pZVH14 clone was less active than pZVB70,
it transactivated HIV CAT in the T-cell line HSB-2 and in
primary T cells. Of interest was the observation that this
fragment, pZVH14, was unique in transactivating the mutant
NFKB promoter even in the absence of antigenic stimula-
tion. No such activity was seen after GS infection of T cells
or transfection of primary T cells with the two transactivat-
ing DNA fragments from GS, pZVB70 and pZVB10. These
data also suggest that the gene products expressed from
pZVH14 are able to act on regions other than the NFKB site,
independent of antigenic stimulation. This also implies that
gene expression from this DNA fragment is possible even
without overt cellular stimulation. Since transactivation of
the mutant NFKB was not observed during an actual infec-
tion with HHV-6(GS), the gene(s) contained within the
pZVH14 DNA fragment must be under some type of regu-
latory control. A recent study has shown that the pZVH14
genomic fragment also has oncogenic properties (32). At
present it is not known whether the gene product(s) the
induce transformation in NIH 3T3 cells is the same prod-
uct(s) responsible for transactivation of the HIV promoter.
The immunodeficiency disease AIDS is a chronic disease
caused by the human retrovirus HIV. The time from HIV
infection to the clinical manifestation of AIDS can range
from 2 months to more than a decade (2, 15, 16). An
important determinant of the length of this latency period is
the rate of HIV replication. Factors that accelerate HIV
replication increase the progression of the disease. After
HIV infection of human T cells in vitro, the virus undergoes
a form of latency until activated by mitogens or specific
antigens (42). In vitro stimulation of T cells increases HIV
promoter activity (13, 40), which can terminate HIV latency.
Thus, activation of the HIV promoter can be a factor in the
length of the latency period. On the basis of their ability to
activate the HIV promoter, other DNA viruses, such as
herpes simplex virus type 1, cytomegalovirus, Epstein-Barr
virus (22), papovaviruses (11), adenoviruses (28), and hepa-
titis B virus (36), have been implicated as possible cofactors
in AIDS. Recent studies have shown that the herpesvirus
cytomegalovirus enhances the replication of HIV in coin-
fected cells (37), and cells productively infected with both
CMV and HIV have been found in the brains of AIDS
patients (29). These studies indicate that it is possible for
DNA viruses, especially herpesviruses, to activate HIV
even in vivo.
HHV-6 infects primarily CD4+ human T cells, the same
cells infected with HIV. Several investigators have shown
that peripheral blood mononuclear cells can be productively
coinfected with HHV-6 and HIV (6, 24, 26). In fact, many of
the initial HHV-6 strains were isolated from individuals
suffering from AIDS (25, 35, 39). Therefore, it seems likely
that coinfection of human T cells with HHV-6 and HIV
could accelerate the immunodeficiency disease caused by
HIV. Ensoli et al. (8) showed that T-cell line HSB-2 could be
productively coinfected with HHV-6 and HIV, resulting in
accelerated cell death and increased HIV transcription. In
the present study, the HIV promoter was activated in
HHV-6-infected, primary human T lymphoblasts. In con-
trast, recent reports have shown that coinfection of periph-
eral blood mononuclear cells with HHV-6 and HIV sup-
pressed HIV replication (6, 24). The differences between
these studies may be due to the nature of the cells that were
infected, dosage of virus, and time of infection. In the
present study, 85 to 89% of the transfected cells were human
T lymphoblasts, whereas the other studies (6, 24) used
stimulated peripheral blood mononuclear cells which con-
tained a variety of cell types. It has been demonstrated that
HHV-6 infects numerous cell types present in peripheral
blood mononuclear cells, including monocytes and B cells
(25, 26, 39). Since the mechanism of HIV inhibition by
HHV-6 in these studies is not known, it still remains possible
that HHV-6 infection of cell types other than T cells con-
tributes to suppression of HIV replication through cytokine
production.
This study has demonstrated that HHV-6 gene products
can activate the HIV promoter in primary human T lympho-
blasts. Therefore, an active HHV-6 infection of human T
cells can activate an otherwise quiescent HIV promoter.
This promoter activation can lead to an increased HIV
replication and consequently enhances T-cell death. In ad-
dition, the replication of HHV-6 itself is cytopathic for T
cells, which would start a cycle of increased T-cell death. By
this proposed mechanism, an active HHV-6 infection would
accelerate the progression of AIDS.
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